GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioxytran Inc (OTCPK:BIXT) » Definitions » Debt-to-Asset

BIXT (Bioxytran) Debt-to-Asset : 5.87 (As of Sep. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Bioxytran Debt-to-Asset?

Bioxytran's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.93 Mil. Bioxytran's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. Bioxytran's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $0.16 Mil. Bioxytran's debt to asset for the quarter that ended in Sep. 2024 was 5.87.

Bioxytran Debt-to-Asset Historical Data

The historical data trend for Bioxytran's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioxytran Debt-to-Asset Chart

Bioxytran Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.87 4.95 17.83 5.84 13.95

Bioxytran Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.19 13.95 7.72 6.50 5.87

Competitive Comparison of Bioxytran's Debt-to-Asset

For the Biotechnology subindustry, Bioxytran's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioxytran's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioxytran's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Bioxytran's Debt-to-Asset falls into.


Bioxytran Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Bioxytran's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1.925 + 0) / 0.138
=13.95

Bioxytran's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.934 + 0) / 0.159
=5.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioxytran  (OTCPK:BIXT) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Bioxytran Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Bioxytran's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioxytran Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioxytran Inc (OTCPK:BIXT) » Definitions » Debt-to-Asset
Comparable Companies
NTBL ACST PIRS AURX CLCS AIM MRKR NBIO AGE CLRB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
75 2nd Avenue, Suite 605, Needham, MA, USA, 02494
Website
https://www.bioxytraninc.com
Bioxytran Inc is a biopharmaceutical company. The company is engaged in developing anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia. It is also focusing on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. Its product candidate, BXT-25, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked.
Executives
David Platt director, 10 percent owner, officer: CEO 12 APPLETON CIRCLE, NEWTON MA 02459
Dale H Conaway director 189 WELLS AVE, NEWTON MA 02459
Alan M Hoberman director 6134 MECHANICSVILLE ROAD, PO BOX 56, MECHANICSVILLE PA 18934
Anders Utter director BIOXYTRAN, INC, 233 NEEDHAM ST., SUITE 300, NEWTON MA 02464
Hana Chen-walden director 7 RUE ARISTIDE MAILLOL, PARIS I0 75015
Michael Sheikh officer: Chief Communication Officer 1905 S AUDUBON CT, SPOKANE WA 99224
Binder Offer other: No longer 10% owner PASQUALE VIA SETTEMBRIMI 14A, SAN MARIANO 06073, CORCIANO PG ITALY L6 00000
Ola Soderquist 10 percent owner, officer: CFO 47 HAMMOND STREET, UNIT 2, WALTHAM MA 02451
Lawrence W. Bonafide director 78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Nathan Marks director 78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Dave Quincy Farber director, officer: President 78365 HWY 111, SUITE 287, LA QUINTA CA 92253
David Lee director 78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Donita R. Kendig director, officer: Secretary/Treasurer 78365 HWY 11, SUITE 287, LA QUINTA CA 92253
Afcc, Llc 10 percent owner 1621 CENTRAL AVENUE, CHEYENNE WY 82001
Paul W Hai 10 percent owner 20443 TIMBERLINE, BEND OR 97701